Board meeting on Nov 4 to approve Q2 results, analyst call the same day
Biocon's board is scheduled to meet on Wednesday, November 04, 2026 to approve and take on record the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
By ScoutQuest · · 2 min read
- Board Meeting Date
- Wednesday, November 04, 2026
- Earnings Call Time
- 16:00 hrs IST on November 04, 2026 over Zoom
- Trading Window Closed
- October 01, 2026 to November 06, 2026; reopens on Saturday, November 07, 2026
What the board meeting covers
- The board is scheduled to meet on Wednesday, November 04, 2026.
- The stated purpose is to approve and take on record the un-audited standalone and consolidated financial results for the quarter and half year ended September 30, 2026.
- The update also refers to other matters, so the results are the main but not the only item listed for the meeting.
Earnings call details
- The company will organise a Q2 FY 2026-27 earnings conference call for analysts and investors on Wednesday, Nov 4, 2026 at 16:00 hrs IST, conducted over Zoom.
- The call follows the announcement of the financial results for the quarter ended Sep 30, 2026.
- The audio recording will be available before the next trading day or within 24 hrs from the end of the call, whichever is earlier.
- The video recording will be available within 48 hrs from the end of the call.
- The transcript will be posted within 5 working days of the call's conclusion, on the company website under Biocon > Investors > Financial Information.
- Participants are asked to join 10 minutes before the scheduled start time.
Trading window
- The trading window for dealing in the company's securities has been closed from Thursday, October 01, 2026 to Friday, November 06, 2026, both days inclusive.
- It will open on Saturday, November 07, 2026.
How to read this
- This is a scheduling intimation: it fixes the date on which the quarterly numbers become public and the forum where management takes questions.
- For a reader tracking the company, the call is the point where management discusses the quarter; the recording and transcript give those who cannot attend live a way to hear it later.
- The intimation itself contains no financial figures for the quarter; the numbers arrive with the results.
Points to note on the call
- The update carries a safe harbour note stating that statements made on the call may be forward-looking and subject to known and unknown risks and uncertainties.
- It lists factors such as general economic and business conditions in India and overseas, the ability to implement strategy, research and development efforts, growth and expansion plans, technological changes, currency movements, interest rate changes, regulatory changes in the biotechnology and pharmaceuticals industries, competition and political conditions.
- The company states it assumes no obligation to update forward-looking statements made on the call.
Also from Biocon
Biocon to hold Q2 FY2026-27 earnings conference call with analysts and investors on November 4, 2026
26 Oct 2026
License agreement with Janssen clears Yesintek market entry in additional global markets
26 Oct 2026
Global patent settlement with Genentech secures earliest licensed launch dates for Pebrilzo® (bPertuzumab)
14 Oct 2026
More numbers
- Audio recording availability after the call24 hrs
- Video recording availability after the call48 hrs
- Transcript availability after the call5 working days
- Advance joining time for participants10 minutes
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.